Direct therapeutic gene transfer is a promising tool to treat articular cartilage defects. Here, we tested the ability of an recombinant adeno-associated virus (rAAV) insulin-like growth factor I (IGF-I) vector to improve the early repair of cartilage lesions in vivo. The vector was administered for 3 weeks in osteochondral defects created in the knee joints of rabbits compared with control (lacZ) treatment and in cells that participate in the repair processes (mesenchymal stem cells, chondrocytes). Efficient IGF-I expression was observed in the treated lesions and in isolated cells in vitro. rAAV-mediated IGF-I overexpression was capable of stimulating the biologic activities (proliferation, matrix synthesis) both in vitro and in vivo. IGF-I treatment in vivo was well tolerated, revealing significant improvements of the repair capabilities of the entire osteochondral unit. IGF-I overexpression delayed terminal differentiation and hypertrophy in the newly formed cartilage, possibly due to contrasting effects upon the osteogenic expression of RUNX2 and β-catenin and to stimulating effects of this factor on the parathyroid hormone/parathyroid hormone-related protein pathway in this area. Production of IGF-I improved the reconstitution of the subchondral bone layer in the defects, showing increased RUNX2 expression levels in this zone. These findings show the potential of directly applying therapeutic rAAVs to treat cartilage lesions.
INTRODUCTION
Despite the availability of various surgical options, defects in the articular cartilage do not heal properly as the repair tissue that forms in the lesions does not display the native structural and mechanical properties of the intact cartilage, owing to the limited ability of the adult cartilage to heal in the absence of vascularization, and of regenerative cells. As a consequence, the repair tissue appears fibrocartilaginous in nature (type-I collagen instead of the native type-II collagen with proteoglycans) without complete integration in the surrounding cartilage and unable to withstand mechanical stress.
Gene transfer is a promising tool to develop strategies that aim at treating cartilage defects as it allows for a stable delivery of therapeutic sequences in the lesions in contrast to the administration of recombinant factors with relatively short half-lives. Direct delivery of the gene vector may be more advantageous as it is a less invasive procedure compared with the administration of genetically modified cells in a biocompatible material. Identification of an effective therapeutic candidate sequence is of the utmost importance for cartilage repair. Different factors have been described for their ability to influence the healing processes in experimental models in vivo, including the transforming growth factor-β, [1] [2] [3] bone morphogenetic proteins, 4-9 fibroblast growth factor-2 (FGF-2), 10, 11 connective tissue growth factor, 12 specific transcription factors (members of the SOX family, ZNF145) [13] [14] [15] [16] and other molecules such as chondromodulin 1 and cartilagederived morphogenetic protein 1. 17, 18 However, complete cartilage repair has not been reported so far with these factors, showing the necessity to apply other agents to extend the processes of healing. The insulin-like growth factor I (IGF-I) is a good candidate to achieve this goal as cartilage repair has been previously noted upon administration of the recombinant factor mixed (or not) with cells and biomaterials in cartilage lesions in vivo. [19] [20] [21] [22] Application of cells (chondrocytes, mesenchymal stem cells (MSCs)) modified to overexpress IGF-I via non-viral or adenoviral vector gene transfer has also been reported in cartilage defects using different types of scaffolds. [23] [24] [25] [26] In addition to the complexity of such an indirect approach, the use of non-viral and adenoviral vectors is still restricted by their low efficacy and/or immunogenicity. Instead, vectors derived from the human nonpathogenic, replication-defective adeno-associated virus (AAV) have promising features for in vivo therapy as recombinant AAV (rAAV) vectors do not carry viral coding sequences, making them less immunogenic. Also, rAAV can efficiently and durably transduce MSCs and chondrocytes in vitro, in situ and directly in cartilage defects in vivo 3, 10, 14, [27] [28] [29] [30] owing to their small size and maintenance as episomes, avoiding also the risk for insertional mutagenesis inherent to the retroviral vectors. To our best knowledge, direct application of rAAV to deliver an IGF-I sequence in cartilage lesions in vivo has not been attempted to date. Based on our previous work showing that direct administration of such a vector can stimulate both the proliferative and anabolic activities (production of major matrix components) of human normal and osteoarthritic articular chondrocytes in their matrix in situ, 30 we tested the hypothesis that the vector can directly deliver a functional IGF-I gene cassette in experimental osteochondral defects in vivo and in cells participating in the repair processes. For the first time, we examined the effects of rAAV-mediated IGF-I overexpression upon the metabolic activities of rabbit bone marrow-derived MSCs and articular chondrocytes in vitro and on the early improvement of the repair tissue in osteochondral defects in the rabbit knee joint compared with control (reporter gene vector) treatment, with an attempt at identifying the pathways possibly implicated in the healing processes.
RESULTS

Effects of rAAV-mediated IGF-I overexpression in vitro
The candidate (rAAV-human IGF-I (rAAV-hIGF-I)) and control (rAAV-lacZ) vectors were first applied to rabbit MSCs and rabbit articular chondrocytes in monolayer culture to monitor transgene expression in vitro in cells relevant to the repair tissue in osteochondral defects. Successful, prolonged IGF-I expression was noted in IGF-I-treated MSCs and chondrocytes compared with lacZ-treated cells (up to day 21) (Figure 1) , showing transduction efficiencies of~75-82% in both cell types. These findings were corroborated by an analysis of the well-maintained, significant IGF-I concentrations produced over time in the IGF-I-versus lacZtreated cultures (up to 24.3-fold, P ⩽ 0.001) ( Table 1) , with higher levels achieved in MSCs compared with the chondrocytes (up to 4.2-fold difference, P ⩽ 0.001).
The vectors were next provided to rabbit MSCs and articular chondrocyte using similar experimental conditions to test the effects of rAAV IGF-I upon cell proliferation and extracellular matrix synthesis in vitro compared with lacZ. Treatment with IGF-I significantly increased the proliferative activities of both cell types at any time point evaluated as noted by the DNA contents (up to 19.3-fold, P ⩽ 0.001) and their anabolic activities as reflected by the contents of proteoglycans (up to 18.9-fold, P ⩽ 0.001) and type-II collagen (up to 18.3-fold, P ⩽ 0.001), compared with lacZ transduction (Table 1) . While the levels of activities were well maintained over time in IGF-I-treated chondrocytes with relatively moderate decreases (o 1.6-fold, P ⩽ 0.001), possibly because of the well-known shift in chondrocyte phenotype upon cell expansion, those in MSCs were continually stimulated (up to 2.5-fold increase, P ⩽ 0.001), possibly because of the higher levels of IGF-I expression produced from rAAV-hIGF-I in these samples.
IGF-I overexpression in osteochondral defects in vivo by direct rAAV application The IGF-I vector was next directly applied in a relevant model of osteochondral defect in rabbits using a previously tested dose 10, 14 to mimic the clinical case where the defect penetrates through the subchondral bone to determine whether overexpression of the factor can be achieved early on (3 weeks) in vivo versus lacZ. Macroscopic examination of the knees revealed that the IGF-I and lacZ defects were filled to the level of the articular cartilage surface with a repair tissue well integrated with the surrounding cartilage ( Figure 2 ). The color of the new tissue resembled that of the host cartilage, but the defect margins were still visible. rAAV application was always well tolerated, without signs of synovitis, adhesions or adverse reactions, and no macroscopically descriptive differences between joints that received IGF-I or lacZ. This was confirmed by a lack of infiltrated immune cells in all defects as noted on tissue sections screened for CD3-(T lymphocytes), CD11b-(activated macrophages) and HLA-DRα-positive cells (class II major histocompatibility complex antigens), in agreement with previous findings using this class of vector. 10, 14 On histologic sections of IGF-I knees, IGF-I expression was detectable compared with lacZ ( Figure 2) , showing reactivity in cells forming the repair tissue through the full thickness and in chondrocytes of the surrounding intact cartilage, primarily localized within the internal zones adjacent to the defects, with very mild staining in few parts of the synovium, quadriceps muscle adjacent to the patella and infrapatellar fat pad, 10, 14 and with expression always much lower than in the defects (always o3% of cells). There was no significant difference in the amounts of IGF-I present in the synovial fluids of the IGF-I-versus lacZ-treated animals (0.29 ± 0.07 versus Figure 1 . Detection of IGF-I transgene expression in rabbit MSCs and rabbit articular chondrocytes in vitro following rAAV-mediated gene transfer. The rAAV-lacZ and rAAV-hIGF-I vectors were provided to monolayer cultures of primary rabbit MSCs or articular chondrocytes (40 μl each vector) for 21 days as described in the Materials and Methods section. Samples were fixed and immunohistochemically stained as described in the Materials and Methods section to monitor transgene expression by analyzing reactivity to IGF-I (magnification x20).
0.26 ± 0.04 ng ml − 1 , P = 0.780). Transgene expression was never noted in the subchondral bone marrow and more distant marrow (central cavity of the femora). Overall, these data showed that there was no undesirable leakage of the gene product in unwanted targets.
Effects of direct rAAV IGF-I overexpression upon the healing of osteochondral defects in vivo The knees were next processed to evaluate the effects of IGF-I upon the metabolic and reparative activities in the defects in vivo. Enhanced healing and organization of the repair tissue was visible on histologic sections with IGF-I compared with lacZ ( Figure 3 ) by repopulation from MSCs of the marrow. Matrix staining (safranin O) was always more intense in the IGF-I defects compared with lacZ ( Figure 3 ). This was corroborated by the results of a histomorphometric analysis based on an estimation of the safranin O staining intensities (1.8-fold difference between IGF-I and lacZ defects, P ⩽ 0.001) ( Table 2) and of a biochemical analysis of the proteoglycan contents in the defects (1.2-fold difference, P = 0.010) ( Table 2) in agreement with the results in vitro. IGF-I treatment also resulted in a better organization of round cells as typical columns in the defects, while cells did not have this appearance with lacZ ( Figure 3) . A histomorphometric analysis of the cell densities in the defects revealed a significant increase with IGF-I versus lacZ (1.5-fold, P ⩽ 0.001) ( Figure 3 and Table 2 ). This was corroborated by a biochemical analysis of the DNA contents in the defects (3.2-fold increase, P ⩽ 0.001) ( Table 2 ) as also noted in vitro.
When the sections were graded for cartilage repair 31 (Table 3) , a significant improvement was noted in the presence of IGF-I for all the parameters included in the evaluation system as well as for the total score compared with lacZ (P ⩽ 0.001) (Table 4) . Overall, these findings were in good agreement with the histomorphometric analysis (Table 2 ). An analysis of the percents of osseous tissue present in the defects on Goldner's trichrome-stained sections further showed that IGF-I treatment significantly enhanced the reconstitution of subchondral bone in these defects compared with lacZ (43 ± 3% versus 12 ± 2%, 3.6-fold, P ⩽ 0.001) ( Figure 3 ).
The sections were next evaluated to monitor the expression of major extracellular matrix components. Type-I collagen reactivity decreased in the IGF-I defects relative to lacZ ( Figure 3 ). This was corroborated by a histomorphometric analysis (1.6-fold difference between IGF-I and lacZ, P ⩽ 0.001) ( Table 2 ). Type-II collagen reactivity was always stronger in the IGF-I defects compared with lacZ ( Figure 3 ). This was also corroborated by histomorphometry (1.5-fold difference between IGF-I and lacZ, P ⩽ 0.001) ( Table 2) and by a biochemical analysis of the type-II collagen contents in the defects (2.8-fold difference, P ⩽ 0.001) ( Table 2 ) again as seen in vitro. Besides, focal type-X collagen staining noted at high levels in the deep zone of the lacZ defects significantly decreased when applying IGF-I (41.5-fold, P ⩽ 0.001) ( Figure 3 and Table 2 ).
Potential pathways involved in healing processes in osteochondral defects in vivo via direct application of rAAV-hIGF-I To address the mechanisms possibly involved in the process of defect healing, we examined the expression of differentiationrelated factors over time, including SOX9 (transcription factor for early chondrogenesis), MMP-13 (matrix metalloproteinase-13; collagenase-3 and marker of terminal differentiation), RUNX2 (runt-related transcription factor-2; transcription factor for Figure 2 . Detection of IGF-I expression in rabbit osteochondral defects in vivo following rAAV-mediated gene transfer. The rAAV-lacZ and rAAV-hIGF-I vectors were directly applied to rabbit osteochondral defects in vivo (10 μl vector) for 3 weeks as described in the Material and methods section. Samples were further fixed, dehydrated, embedded in paraffin, cut and immunohistochemically stained as described in the Materials and Methods section to monitor transgene expression by analyzing reactivity to IGF-I (magnification x20) in the cartilage zone. Staining is representative of the defects. Macroscopic views of the defects are also presented. rAAV IGF-I to treat osteochondral defects M Cucchiarini and H Madry osteoblast-related genes), the PTH/PTHrP receptor (the receptor for PTHrP, an inhibitor of hypertrophic maturation and calcification) and β-catenin (a mediator of the Wnt signaling pathway for osteoblast lineage differentiation). Application of rAAV-hIGF-I compared with rAAV-lacZ induced significant increases in the expression of SOX9 and of the PTH/PTHrP receptor in the newly formed cartilage in the defects (up to 49-fold increase, P ⩽ 0.001), whereas it significantly decreased that of MMP-13, RUNX2 and β-catenin (up to 85-fold decrease, P ⩽ 0.001) ( Figure 4 and Table 2 ). Most interestingly, IGF-I treatment significantly increased the expression of RUNX2 in the subchondral bone of the defects compared with lacZ (4.6-fold increase, P ⩽ 0.001) (insets of Figure 4 and Table 2 ).
DISCUSSION
Direct delivery of therapeutic genes to cartilage defects is an attractive approach to allow for a sustained healing of the lesions compared with the application of recombinant factors with short half-lives or with the more invasive transplantation of genetically modified cells. rAAV vectors are valuable systems to achieve this goal as they can efficiently and persistently transduce MSCs and chondrocytes in vitro, in situ and directly in cartilage defects in vivo without detrimental effects. 10, 14, [27] [28] [29] [30] Among the various candidates previously tested for their reparative activities in cartilage defects in vivo (transforming growth factor-β, bone morphogenetic proteins, FGF-2, connective tissue growth factor, SOX, ZNF145, chondromodulin 1, cartilage-derived morphogenetic Figure 3 . Histologic and immunohistochemical analyses in rAAV-transduced rabbit osteochondral defects. The rAAV-lacZ and rAAV-hIGF-I vectors were directly applied to rabbit osteochondral defects in vivo (10 μl vector) for 3 weeks as described in Figure 2 and in the Materials and Methods section. Samples were further fixed, dehydrated, embedded in paraffin, cut and stained with safranin O or with the Goldner's trichrome method (both at magnification x2) or immunohistochemically stained as described in the Materials and Methods section to monitor the expression of type-I (magnification x4), type-II (magnification x2) and type-X collagen (magnification x20; view of the deep cartilage zone). Staining is representative of the defects.
rAAV IGF-I to treat osteochondral defects M Cucchiarini and H Madry protein 1), none allowed for a consistent healing of the lesions, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] showing the need to identify other factors with improved reparative capacities. Here, for the first time to our best knowledge, we investigated the ability of rAAV-mediated IGF-I overexpression to enhance the repair of osteochondral defects in rabbit knee joints early on following direct, local gene transfer in light of reports showing partial effects of a recombinant growth factor [19] [20] [21] [22] or of IGF-I gene transfer using less efficient non-viral and adenoviral vectors in complex indirect strategies, [23] [24] [25] [26] and based on our own findings that the present rAAV IGF-I vector can significantly remodel human osteoarthritic cartilage. 30 The data indicate that sustained transgene expression can be achieved in rabbit MSCs and chondrocytes in vitro over time (up to 21 days) at high efficiencies (up to 82%), consistent with previous reports in these cell types 14 or when applying the present IGF-I vector to human chondrocytes. 30 The data further show that IGF-I overexpression significantly promoted the proliferative and anabolic activities (synthesis of proteoglycans and type-II collagen) in both populations, in good agreement with the properties of the growth factor 32 and with previous findings in rAAV IGF-I-treated human chondrocytes. 30 The high and prolonged levels of IGF-I achieved via rAAV gene transfer in MSCs are probably the cause of the elevated amounts of type-II collagen produced by the cells. This is in marked contrast with previous findings showing that the growth factor does not promote the chondrogenesis of MSCs; 33, 34 however, it is important to note that these earlier studies focused on the use of adenoviral vectors that allowed only for short-term IGF-I expression (about a week), probably not enough to permit differentiation at day 21. Remarkably, slow, sustained release of recombinant IGF-I from biomaterials has been shown to mediate the chondrogenic differentiation of MSCs after 21 days, 35 supporting our present findings with rAAV. Interestingly, the effects of IGF-I overexpression upon the biologic activities of the cells were overall more robust in MSCs than in chondrocytes, possibly reflecting the shift in phenotype in the latter cell type during expansion in culture. The data further show that direct administration of rAAV IGF-I in rabbit osteochondral defects in vivo led to elevated, well-localized, homogeneous expression of the growth factor in cells filling the repair tissue, with only mild reactivity in surrounding chondrocytes, synovium, quadriceps muscle and infrapatellar fat pad, while expression was absent in the subchondral bone marrow and distant marrow, in agreement with previous findings when applying other types of rAAV vectors in similar models. 10, 14 Administration of the candidate rAAV IGF-I vector was well tolerated as previously reported.
10,14 and in 4 Remarkably, IGF-I treatment significantly enhanced the individual and overall parameters of healing of the defects compared with lacZ, probably due to the strong levels of IGF-I expression achieved via rAAV administration. Concordant with this, stronger matrix and type-II collagen staining intensities were also noted in the IGF-I-treated cartilage repair tissue (with a more homogeneous distribution for proteoglycans, possibly becasue of more potent effects of IGF-I compared with type-II collagen) relative to the lacZ condition showing a repair tissue of mostly fibrocartilaginous (type-I collagen) nature, probably due increased SOX9 and decreased MMP-13 expression in this zone, all in agreement with the properties of IGF-I. 30, [36] [37] [38] [39] [40] In contrast, the type-I collagen staining intensities and the percents of cells positive for type-X collagen advantageously diminished in the newly formed cartilage tissue through rAAV-mediated IGF-I production in the defects, possibly because of a local reduction of the levels of MMP-13 (hypertrophy marker) and RUNX2 (a transcription factor controlling osteoblastic expression markers such as COL I, COL X and MMP-13). 37, 39, 41, 42 Interestingly, treatment with IGF-I instead led to increases in RUNX2 expression in the subchondral bone of the defects, probably allowing for the improved subchondral bone reconstitution noted in this condition, also consistent with the effects on the growth factor upon osteogenic differentiation and bone formation. [43] [44] [45] These findings suggest that the mechanisms of regulation via rAAV IGF-I gene transfer might be different in the subchondral bone compared with the cartilage tissue area in osteochondral defects. Of further note, the reparative effects of IGF-I achieved here via stable rAAV-mediated growth factor overexpression were accompanied by increased levels of the PTH/PTHrP receptor (the receptor for PTHrP, an agent known to inhibit hypertrophic maturation and calcification) and decreased levels of β-catenin (a mediator of the Wnt signaling pathway for osteogenic differentiation) in the cartilage repair tissue, again possibly explaining the delay in hypertrophy and consistent with previous findings. 36, 42, 46 For comparison, improved cartilage repair was also reported in similar models when providing IGF-I as a recombinant molecule with short half-life, [19] [20] [21] [22] although very high doses of the factor were needed to achieve therapeutic effects (25 μg in horses, 200 ng in rabbits). On the other side, expression of IGF-I via implantation of non-virally [24] [25] [26] or adenovirally modified cells 23 (chondrocytes, MSCs) in a biomaterial also promoted cartilage repair in vivo. In contrast to such a complex approach, the current strategy based on highly efficient and safe rAAV vectors may provide convenient (one-step) options to treat cartilage lesions, showing again the strong value of this class of vector for clinically relevant gene transfer protocols. In summary, our results demonstrate the benefits of direct rAAV IGF-I overexpression to safely improve the early healing of articular cartilage defects in vivo compared with control treatment. Additional studies are required to test the long-term effects of the approach and estimate the biomechanical properties of the repair tissue in vivo. It remains to be seen whether codelivery of other factors via rAAV will be needed to strengthen the IGF-Imediated regenerative processes over time. Such an approach has been already successfully evaluated by Morisset et al. 47 via coapplication of IGF-I with an interleukin-1 receptor antagonist. While transforming growth factor-β might not be the best candidate to achieve this goal, 20, 21 possibly other candidates such as bone morphogenetic proteins, 4-9 FGF-2, 10,11 connective tissue growth factor, 21 members of the SOX family of transcription factors or ZNF145, 13-16 chondromodulin 1 18 or cartilage-derived morphogenetic protein 1 might. 17 Administration of independent rAAV vectors may be feasible in vivo, without interference between constructs, in light of evidence showing the successful, concomitant gene transfer of FGF-2 with SOX9 for the remodeling of human osteoarthritis cartilage in situ. 48 Taken together, the current findings provide motivation to further elaborate direct therapeutic rAAV-mediated gene transfer strategies for the treatment of human cartilage defects.
MATERIALS AND METHODS Materials
Reagents were from Sigma (Munich, Germany), unless otherwise indicated. The anti-IGF-I (AF-291-NA) antibody was from R&D Systems (WiesbadenNordenstadt, Germany). The anti-HLA-DRα (TAL.1B5) antibody was from Dako (Hamburg, Germany). The anti-CD3 (PC3/188A), anti-SOX9 (C-20), anti-MMP-13 (72B-01), anti-RUNX2 (S-19), anti-PTH/PTHrP receptor (3D1.1) and anti-β-catenin (E-5) antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany). The anti-type-I collagen (AF-5610), anti-type-II collagen (AF-5710) and anti-CD11b (Ly-40) antibodies were from Acris (Hiddenhausen, Germany). The anti-type-X collagen (COL-10) antibody was from Sigma. Biotinylated secondary antibodies and ABC were from Vector Laboratories (Alexis Deutschland, Grünberg, Germany). The Quantikine IGF-I ELISA was from R&D Systems. The type-II collagen Arthrogen-CIA Capture ELISA was from Chondrex (Redmond, WA, USA).
Cells
Bone marrow aspirates (~5 ml) were obtained from rabbit distal femurs (n = 4) and MSCs were isolated and expanded using standard protocols. 27, 28 Rabbit chondrocytes were isolated from articular cartilage (n = 4) and maintained as described. [10] [11] [12] [13] [14] All assays were performed with cells at passage 2, on days 10-14 after isolation. The 293 cell line, an adenovirus-transformed human embryonic kidney line, was maintained in Eagle's minimal essential medium containing 10% fetal bovine serum and antibiotics.
Plasmids and rAAV vectors
The constructs and pACP were derived from pSSV9, an AAV-2 genomic clone. 49, 50 rAAV-lacZ carries the lacZ gene (β-gal) controlled by the cytomegalovirus immediate-early promoter. 10, 14, [27] [28] [29] [30] rAAV-hIGF-I carries a 0.54-kb hIGF-I cDNA cloned in rAAV-lacZ in place of lacZ. 30 rAAV were packaged as conventional (not self-complementary) vectors using a helper-free, two-plasmid transfection system in the 293 cell line with the packaging plasmid pXX2 and the adenovirus helper plasmid pXX6 as described previously. 29 The preparations were purified by dialysis and titered by real-time PCR, 10,14,27-30 averaging 10 10 transgene copies per ml. 14,27-29 MSCs were kept in Mesencult Basal Medium, MSC Stimulatory Supplements (StemCell Technologies, Cologne, Germany), 100 U ml − 1 penicillin and 100 μl ml − 1 streptomycin (pen-strep), rFGF-2 (10 ng ml − 1 ) for up to 21 days. 27, 28 Chondrocytes were kept in Dulbecco's modified Eagle's medium, pen-strep, 10% fetal bovine serum (growth medium) for up to 21 days. 10, 14, 29, 30 Gene transfer to articular cartilage defects in vivo All procedures were approved by the Saarland University Animal Committee according to German guidelines. 10, 14 Eight 10,14 female chinchilla bastard rabbits (2.7 ± 0.4 kg; Charles River, Sulzfeld, Germany) were used in the study. The animals were in their late juvenile stage by histologic analysis of their growth plate, which contained few layers of chondrocytes. Two cylindrical osteochondral defects were created in each patellar groove (n = 32 defects) with a manual cannulated burr (3.2 mm in diameter) (one defect for histologic and immunohistochemical analyses, the other defect for biochemical assays). Care was taken not to perforate the subchondral plate. Defects were washed with saline and blotted dry and rAAV vectors were applied to each defect using a previously tested dose (10 μl, i.e. 2 × 10 5 functional recombinant viral particles). 10, 14 Each animal received rAAV-lacZ on one knee and rAAV-hIGF-I on the contralateral knee and treatments were evenly distributed between right and left knees. After 3 weeks, the animals were killed and the knee joints examined grossly for synovitis, contractures, adhesions or other adverse reactions. The appearance of the repair tissue (color, integrity, contour) and articular surfaces was noted. The distal femora with adjacent synovium were removed and subjected to transgene expression, histologic and biochemical analyses. Figure 4 . Potential pathways involved in the healing processes in rAAV-transduced rabbit osteochondral defects. The rAAV-lacZ and rAAVhIGF-I vectors were directly applied to rabbit osteochondral defects in vivo (10 μl vector) for 3 weeks as described in Figures 2 and 3 and in the Materials and Methods section. Samples were further fixed, dehydrated, embedded in paraffin, cut and immunohistochemically stained as described in the Materials and Methods section to monitor the expression of SOX9, MMP-13, RUNX2, PTH/PTHrP receptor and β-catenin in the cartilage zone. Staining is representative of the defects (all are views of the deep cartilage zone of the defect, except for the PTH/PTHrP receptor: middle cartilage zone). Insets show RUNX2 immunostaining in the subchondral bone. All at magnification x10.
Transgene expression
To assess IGF-I secretion in vitro, samples were washed two times and placed for 24 h in serum-free medium. Supernatants were collected at the denoted time points and centrifuged. IGF-I production was also measured in samples from synovial fluid of rabbits by enzyme-linked immunosorbent assay on a GENios spectrophotometer/fluorometer (Tecan, Crailsheim, Germany). 30 Expression was monitored by immunocytochemical and immunohistochemical analyses with specific primary antibodies, biotinylated secondary antibodies and the ABC method using diaminobenzidine as the chromogen. 10, 14, [27] [28] [29] [30] To control for secondary immunoglobulins, samples were processed with omission of primary antibodies. Samples were examined under light microscopy (Olympus BX 45, Hamburg, Germany). Specific immunostaining was examined within the repair tissue and in the intact surrounding cartilage, as well as in the synovium, quadriceps muscle adjacent to the patella, infrapatellar pad, subchondral bone marrow and bone marrow in the central cavity of the femora. 10, 14 Histological, immunocytochemical and immunohistochemical analyses
The samples were fixed in 10% buffered formalin. Knees were dehydrated in graded alcohols and embedded in paraffin. 10, 14, [27] [28] [29] [30] Paraffin-embedded sections (5 μm) were processed for safranin O and hematoxylin/eosin staining 10, 14, [27] [28] [29] [30] or for Goldner's trichrome staining. 14 Serial sections were taken at 200 μm intervals within 1.2 mm from the defect center (n = 10-12 per defect) 10, 14 and graded blind by a cartilage repair system scoring nineparameters (a cumulative score of 0 indicates complete regeneration, whereas 31 indicates an empty, unhealed defect) ( Table 3) . 31 Each section was scored and all scores were combined as a total score per group. One hundred and forty-five sections were scored. Sections were also processed for staining with the Goldner's trichrome method (osseous tissue).
14 Expression of CD3, CD11b, HLA-DRα, type-I, type-II, type-X collagen, SOX9, MMP-13, RUNX2, PTH/PTHrP receptor and β-catenin was detected using specific antibodies, biotinylated secondary antibodies, ABC and diaminobenzidine. 10, 14, [27] [28] [29] [30] Morphometric analyses
The transduction efficiencies, cell densities, safranin O staining intensities, percentage of subchondral bone reconstitution (ratio of positively stained osseous tissue area to the total surface of the defect evaluated on Goldner's trichrome-stained sections), the percentage of cells positive for type-X collagen, SOX9, MMP-13, RUNX2 (cartilage zone), PTH/PTHrP receptor and β-catenin immunostaining and the RUNX2 staining intensities (subchondral bone zone) were measured at 3 standardized sites or using 10 serial sections for each parameter, test and replicate condition using SIS AnalySIS (Olympus), Adobe Photoshop (Adobe Systems, Unterschleissheim, Germany) and Scion Image (Scion Corporation, Frederick, MD, USA). 10, 14, [27] [28] [29] [30] The safranin O and subchondral bone RUNX2 staining intensities were in pixels per standardized area. 48 The type-I collagen reactivity in the repair tissue was compared with that of the subchondral bone adjacent to the normal cartilage (positive internal control).
14 The type-II collagen reactivity in the repair tissue was compared with that of the adjacent normal cartilage (positive internal control). 14 The following score was given for each type of collagen reactivity: 0 (no reactivity), 1 (significantly weaker), 2 (moderately weaker), 3 (similar) and 4 (stronger) compared with its respective control. Histologic sections (n = 2-3 per defect and collagen type) were scored blind with regard to the groups.
Biochemical assays
Cell cultures and repair tissue in the defects were processed to monitor the DNA, proteoglycans and type-II collagen contents by Hoechst 33258 assay, binding to DMMB (dimethylmethylene blue) dye and enzyme-linked immunosorbent assay, respectively. 10, 14, [27] [28] [29] [30] Data were normalized to total cellular proteins using a protein assay (Pierce Thermo Scientific, Fisher Scientific, Schwerte, Germany). All measurements were performed with a GENios spectrophotometer/fluorometer (Tecan).
Statistical analysis
Each condition in vitro was carried out in triplicate in three independent experiments and with 32 defects in vivo. Data are as means ± s.d. The t-test and the Mann-Whitney rank-sum test were used for in vitro experiments. For in vivo experiments, points for each category and total score were compared between the two groups using a mixed general linear model with repeated-measures analysis of variance (knees tested within the same animals). Data are as means ± 95% confidence interval. Any P-value of o0.05 was considered statistically significant.
